Poor
Mostly Not Aligned
Patient Risk:
Moderate
Summary
Only a subset of the listed claims are supported by the provided FDA label excerpts (indication, active ingredients, administration method constraints, contraindication hypersensitivity, and key warning about respiratory/CNS depression with alcohol/CNS depressants, plus some adverse events). Many other claims are not addressed by the supplied label text excerpts (e.g., Subutex history/pregnancy, manufacturer/patents/generics, mechanistic receptor activity detail, dosing preference outpatient, controlled substance/DEA statements, efficacy outcomes, and several adverse effects and misuse specifics).
Category Scores
Accurate Statements
Suboxone is used for the treatment of opioid use disorder (OUD).
Indications and Usage excerpt: “indicated for treatment of opioid dependence.”
Suboxone contains buprenorphine and naloxone.
Active ingredients provided in prompt excerpts: buprenorphine and naloxone.
Suboxone is administered sublingually or buccally as a single daily dose (single daily dose concept).
Dosage and Administration excerpt: “administered sublingually or buccally as a single daily dose.” (Only partially reflected because the user did not explicitly state this exact phrasing for dosing frequency/method across all claims.)
Buprenorphine has been associated with life-threatening respiratory depression and death (including risk with alcohol/CNS depressants).
Warnings excerpt: “Buprenorphine has been associated with life‐threatening respiratory depression and death… misuse by self‐injection… concomitant use… including alcohol.”
Serious breathing problems… especially a risk when combined with alcohol or other central nervous system depressants.
Warnings excerpt: concomitant use of buprenorphine and benzodiazepines or other CNS depressants, including alcohol increases risks.
Due to additive pharmacologic effects, concomitant use of benzodiazepines or other CNS depressants, including alcohol, increases the risk of respiratory depression, profound sedation, coma, and death.
Drug Interactions excerpt: “increases the risk of respiratory depression, profound sedation, coma, and death.”
Accidental exposure to naloxone can cause withdrawal symptoms in individuals dependent on opioids.
Not explicitly supported in the provided label excerpts; however withdrawal syndrome is listed among adverse events in clinical trials experience. (Mechanism/‘accidental exposure to naloxone’ is not directly supported; see unsupported.)
Unsupported Statements
Indivior is the primary manufacturer of Suboxone.
No manufacturer information in provided label excerpts.
Generic versions of Suboxone are available.
No generics/patent expiration information in provided label excerpts.
Generic versions of Suboxone are produced by various pharmaceutical companies after the expiration of certain patents.
Not addressed in provided label excerpts.
Different patents related to Suboxone's formulation and its use have had varying expiry dates, with some expiring in the late 2010s and others later.
Not addressed in provided label excerpts.
Buprenorphine is a partial opioid agonist that helps to reduce withdrawal symptoms and cravings.
Label excerpts provided do not state pharmacologic class/mechanism or that it reduces cravings.
Naloxone is an opioid antagonist that discourages misuse of the medication by injecting it.
No naloxone mechanism or discouragement of injection misuse described in provided excerpts.
Suboxone works by binding to opioid receptors in the brain.
No receptor-binding description in provided label excerpts.
Buprenorphine's partial agonist activity activates opioid receptors but to a lesser extent than full agonists like heroin or methadone.
Not described in provided label excerpts.
Suboxone can help stabilize patients.
Not stated in provided label excerpts.
Suboxone can reduce withdrawal symptoms.
Provided label excerpts list “withdrawal syndrome” as an adverse event but do not state therapeutic reduction of withdrawal symptoms.
Suboxone can decrease the desire for other opioids.
Not stated in provided label excerpts.
The naloxone component is inactive when Suboxone is taken as prescribed.
Not addressed in provided label excerpts.
The naloxone component will block the effects of buprenorphine if Suboxone is injected.
Not addressed in provided label excerpts.
Suboxone is intended to deter intravenous abuse.
Not addressed in provided label excerpts.
Common side effects of Suboxone include dizziness.
Not included in the provided ‘most common adverse event (>1%)’ list or the listed other adverse events.
Common side effects of Suboxone include drowsiness.
Not included in provided adverse reaction list.
Common side effects of Suboxone include nausea.
Nausea is not listed; ‘vomiting’ and other oral findings are listed.
Common side effects of Suboxone include vomiting.
Vomiting is listed among other adverse events, but whether it is ‘common’ is not established by the excerpt (only oral hypoesthesia is explicitly labeled as >1%).
Common side effects of Suboxone include headache.
Not listed in provided adverse reaction excerpt.
Common side effects of Suboxone include sweating.
‘hyperhidrosis’ is listed (sweating), but the excerpt does not say it is ‘common’ (>1%).
Common side effects of Suboxone include oral discomfort.
Only ‘oral hypoesthesia’ and other oral mucosal findings are listed; ‘oral discomfort’ is not an exact label phrase.
More serious side effects of Suboxone can include liver problems.
Liver problems are not mentioned in the provided adverse reactions excerpt.
More serious side effects of Suboxone can include breathing difficulties.
Breathing difficulty is consistent with respiratory depression described in warnings, but the excerpt does not list ‘breathing difficulties’ as an adverse reaction category; it states risk association in warnings.
More serious side effects of Suboxone can include the potential for dependence.
Dependence risk is not stated in provided excerpts.
More serious side effects of Suboxone can include withdrawal symptoms upon discontinuation.
Withdrawal syndrome is listed as an adverse event, but ‘upon discontinuation’ is not stated in the provided excerpts.
Suboxone and Subutex are both medications manufactured by Indivior.
No label excerpts provided about Subutex or manufacturer.
Subutex contains only buprenorphine.
No label excerpts provided about Subutex formulation.
Suboxone is generally preferred for outpatient treatment due to the presence of naloxone, which helps prevent misuse.
Not addressed in the provided label excerpts.
Subutex, containing only buprenorphine, was historically used in clinical settings for medical procedures.
Not addressed in provided label excerpts.
Subutex, containing only buprenorphine, was historically used for pregnant individuals.
Not addressed in provided label excerpts.
Subutex prescribing guidelines can vary.
Not addressed in provided label excerpts.
Suboxone is a Schedule III controlled substance.
Controlled substance schedule is not addressed in provided label excerpts.
Suboxone requires a prescription from a qualified healthcare provider.
Prescription requirement is not addressed in provided label excerpts.
Prescribing buprenorphine products like Suboxone requires specific registration with the U.S. Drug Enforcement Administration (DEA).
DEA registration/requirements are not addressed in provided label excerpts.
Suboxone is regulated by the Food and Drug Administration (FDA) in the United States.
Not addressed in provided label excerpts.
The DEA regulates Suboxone's controlled substance status.
Not addressed in provided label excerpts.
Suboxone has demonstrated efficacy in reducing illicit opioid use.
Efficacy outcomes are not included in provided label excerpts.
Suboxone has demonstrated efficacy in improving retention in treatment for opioid use disorder.
Not addressed in provided label excerpts.
Studies have compared Suboxone to placebo and other treatment options.
Not addressed in provided label excerpts.
Compared with placebo and other treatment options, Suboxone has shown significant reductions in opioid use.
Not addressed in provided label excerpts.
Compared with placebo and other treatment options, Suboxone has shown significant reductions in withdrawal symptoms.
Not addressed in provided label excerpts.
Risks associated with Suboxone include the potential for developing dependence.
Not addressed in provided label excerpts.
Risks associated with Suboxone include withdrawal symptoms if stopped abruptly.
Not addressed in provided label excerpts.
Risks associated with Suboxone include liver damage.
Not addressed in provided label excerpts.
Risks associated with Suboxone include serious breathing problems.
Breathing/respiratory depression risk is mentioned in warnings (supported), but the claim categorizes it as a ‘risk’ without stating it in label-excerpt language; still, supported in warnings generally. Marked as unsupported because ‘serious breathing problems’ as phrased is not explicitly listed.
Accidental exposure to naloxone can cause withdrawal symptoms in individuals dependent on opioids.
The excerpt does not connect naloxone exposure to withdrawal; it only lists withdrawal syndrome as an adverse event.
The naloxone component is inactive when Suboxone is taken as prescribed.
Not addressed in provided label excerpts.
Contradictions
Important Omissions
Method-of-administration warnings that the film must be administered whole (not cut/chewed/swallowed) and patients should not eat or drink until dissolved.
Importance:
Moderate
Contraindication detail: hypersensitivity to buprenorphine or naloxone and serious adverse reactions including anaphylactic shock.
Importance:
Moderate
Label-excerpt-supported common adverse event wording (oral hypoesthesia) rather than substituted ‘dizziness/headache’ claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-relevant label elements were not covered (e.g., specific administration instructions about not cutting/chewing/swallowing; contraindication hypersensitivity; and some adverse events are replaced with unsupported ones). However, key warning and interaction themes about respiratory/CNS depression with alcohol/CNS depressants were addressed.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Not Aligned
Primary Issue
Large proportion of claims are not supported by the provided FDA label excerpts (including manufacturer/generics/patent details, Subutex/pregnancy history, pharmacologic mechanism details, controlled substance/DEA statements, efficacy outcomes, and several specific adverse effects). Also missing key administration and contraindication details from the excerpts.
Suggested Improvement
Restrict statements to what is supported by the provided label excerpts: opioid dependence indication; active ingredients; contraindication (hypersensitivity to buprenorphine or naloxone); administration route and whole-film/dissolution instructions; warnings about life-threatening respiratory depression and concomitant alcohol/CNS depressants; and the adverse events listed (oral hypoesthesia >1% and the enumerated other adverse events). Remove or rephrase unsupported claims.